Infinity Pharmaceuticals Inc. (NASDAQ:INFI) – Equities researchers at William Blair issued their Q1 2019 EPS estimates for shares of Infinity Pharmaceuticals in a research report issued on Friday. William Blair analyst Y. Xu expects that the biotechnology company will post earnings of $0.20 per share for the quarter. William Blair also issued estimates for Infinity Pharmaceuticals’ Q2 2019 earnings at ($0.24) EPS, Q3 2019 earnings at ($0.25) EPS and Q4 2019 earnings at ($0.26) EPS.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11.
Separately, ValuEngine downgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
Shares of Infinity Pharmaceuticals stock remained flat at $$2.51 during midday trading on Monday. The company’s stock had a trading volume of 372,352 shares, compared to its average volume of 734,584. Infinity Pharmaceuticals has a 52-week low of $0.93 and a 52-week high of $3.75.
Institutional investors and hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. bought a new stake in Infinity Pharmaceuticals in the second quarter valued at $130,000. JPMorgan Chase & Co. bought a new stake in Infinity Pharmaceuticals in the third quarter valued at $135,000. Alambic Investment Management L.P. bought a new stake in Infinity Pharmaceuticals in the fourth quarter valued at $158,000. Wells Fargo & Company MN increased its stake in Infinity Pharmaceuticals by 654.7% in the fourth quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 91,206 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Infinity Pharmaceuticals by 102.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 75,980 shares in the last quarter. 50.69% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Infinity Pharmaceuticals Inc. to Post Q1 2019 Earnings of $0.20 Per Share, William Blair Forecasts (INFI)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/21/infinity-pharmaceuticals-inc-to-post-q1-2019-earnings-of-0-20-per-share-william-blair-forecasts-infi.html.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.